Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn’s Disease: Real-world Experience From a Large Canadian Center

医学 乌斯特基努马 克罗恩病 内科学 危险系数 回顾性队列研究 单中心 炎症性肠病 胃肠病学 外科 疾病 英夫利昔单抗 置信区间
作者
Rocío Sedaño,Leonardo Guizzetti,Cassandra McDonald,Melanie Beaton,Nilesh Chande,Jamie Gregor,Michael Sey,Aze Wilson,Vipul Jairath
出处
期刊:Inflammatory Bowel Diseases [Oxford University Press]
卷期号:29 (6): 866-874 被引量:8
标识
DOI:10.1093/ibd/izac149
摘要

With the expanding therapeutic armamentarium for inflammatory bowel disease (IBD), real-world data may help inform drug positioning. We assessed clinical, endoscopic, imaging, and biochemical response/remission outcomes in patients with Crohn's disease (CD) treated with ustekinumab in a large Canadian IBD center.A retrospective cohort study of CD patients was treated with ustekinumab. Clinical, endoscopic, radiological, and biochemical response and remission outcomes were stratified by prior biologic exposure status. Hazard ratios for biologic exposure status were estimated using Cox proportional hazard models and subgroup-specific incidence rates for healing.A total of 231 patients (55.9% female, median 45.8 years) were identified as receiving ustekinumab during the study period, with 2 patients subsequently excluded (N = 229). Of these patients, 79.0% (181 of 229) were bio-experienced, with 38.7% (70 of 181) having failed 1 biologic and 61.3% (111 of 181) having failed ≥2 biologics. At 3 months of follow-up after induction, clinical remission (Harvey-Bradshaw Index ≤4) was achieved by 59.1% (62 of 105) of bio-experienced patients and 79.4% (27 of 34) of bio-naïve patients (relative risk [RR], 1.34; 95% CI, 1.06-1.70; P = .013). Endoscopic remission (absence of mucosal ulcers) was achieved in 37.9% (33 of 87) cases. Rate of endoscopic healing (either endoscopic response or remission) per 1000 person-months was 72.7 (95% CI, 42.4-125.1) and 50.2 (37.9-66.4); and the median time to endoscopic response was 8.4 months (95% CI, 6.4-9.8) and 15.4 months (95% CI, 10.3-17.9) in bio-naïve vs bio-experienced patients, respectively. Imaging response/remission and steroid-free remission rates were higher in bio-naïve patients.In this large real-world cohort of CD patients with complex phenotypes and high rates of prior biologic exposure, we observed that ustekinumab was effective and safe with higher rates of improvement in bio-naïve subjects across a range of end points.In this large real-world study of patients with Crohn’s Disease treated with ustekinumab, we observed high rates of clinical, endoscopic, radiological, and biochemical response and remission rates. Effectiveness was greater in bio-naïve compared with bio-experienced patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
山姆完成签到,获得积分10
1秒前
1秒前
1秒前
敏感一一完成签到,获得积分10
2秒前
柏林完成签到,获得积分10
3秒前
小小木发布了新的文献求助10
5秒前
加选完成签到 ,获得积分10
5秒前
xh完成签到,获得积分10
5秒前
zzhui发布了新的文献求助10
7秒前
7秒前
科研通AI6.4的应助被LeeNeaul采纳,获得30
8秒前
colin完成签到 ,获得积分10
8秒前
oldfive完成签到,获得积分10
10秒前
朴素的松完成签到,获得积分10
12秒前
T1Oner完成签到 ,获得积分10
13秒前
aeolianbells完成签到 ,获得积分10
13秒前
14秒前
郭逍遥完成签到,获得积分10
17秒前
elsa嘻嘻完成签到 ,获得积分10
18秒前
lkymxt完成签到,获得积分10
18秒前
明亮的映天完成签到,获得积分10
18秒前
苏以禾完成签到 ,获得积分10
18秒前
20秒前
英姑的应助被凌风采纳,获得10
23秒前
elerain完成签到,获得积分10
23秒前
钙帮弟子完成签到,获得积分10
27秒前
yeroumu3zhi完成签到,获得积分0
28秒前
风禾尽起完成签到,获得积分10
29秒前
科研通AI6.2的应助被yuuuuuuuuuuu采纳,获得10
29秒前
翊然甜周完成签到,获得积分10
30秒前
viczhang完成签到,获得积分10
30秒前
青柠微凉完成签到 ,获得积分10
31秒前
gogogo完成签到,获得积分10
33秒前
科研通AI6.4的应助被LeeNeaul采纳,获得30
34秒前
zhuqiang完成签到,获得积分10
34秒前
执着道之完成签到 ,获得积分10
36秒前
小马完成签到 ,获得积分10
37秒前
whisper完成签到,获得积分10
37秒前
12完成签到 ,获得积分10
37秒前
SciGPT的应助被董阳采纳,获得10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185571
求助须知:如何正确求助?哪些是违规求助? 9574290
关于积分的说明 21834928
捐赠科研通 7783274
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558973
邀请新用户注册赠送积分活动 2481370